Get the Stockscreener App
12.51
7.49%
-1.0993
Dyne Therapeutics Inc Stock (DYN) Latest News
Dyne Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Dyne Therapeutics’ (DYN) Buy Rating Reiterated at Chardan Capital - Defense World
Piper Sandler Cuts Dyne Therapeutics (NASDAQ:DYN) Price Target to $48.00 - Defense World
HC Wainwright Cuts Dyne Therapeutics (NASDAQ:DYN) Price Target to $46.00 - Defense World
Rhumbline Advisers Boosts Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
HC Wainwright Lowers Dyne Therapeutics (NASDAQ:DYN) Price Target to $46.00 - MarketBeat
Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Insider Sells 2,598 Shares of Stock - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Hits New 12-Month LowWhat's Next? - MarketBeat
Dyne Therapeutics stock target cut to $46 at H.C. Wainwright By Investing.com - Investing.com Canada
Dyne Therapeutics price target lowered to $48 from $53 at Piper Sandler - TipRanks
Buy Rating for Dyne Therapeutics: Promising Accelerated Approval Potential for DYNE-101 and DYNE-251 - TipRanks
Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Dyne Therapeutics Advances Clinical Programs Amid Financial Losses - TipRanks
Dyne Therapeutics (DYN) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Dyne Therapeutics Q4 Net Loss Narrows; Shares Rise -February 27, 2025 at 09:42 am EST - Marketscreener.com
Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - The Manila Times
DYNE THERAPEUTICS Earnings Results: $DYN Reports Quarterly Earnings - Nasdaq
Dyne Therapeutics, Inc. Q4 Loss Beats Estimates - Nasdaq
Can Dyne's $783M War Chest and Fast-Tracked DM1 Program Transform Muscle Disease Treatment? - StockTitan
Dyne Therapeutics, Inc. SEC 10-K Report - TradingView
How To Trade (DYN) - Stock Traders Daily
Dyne therapeutics chief scientific officer sells $36,242 in stock By Investing.com - Investing.com South Africa
Dyne therapeutics chief scientific officer sells $36,242 in stock - Investing.com India
Dyne Therapeutics CSO Sells Shares to Satisfy Tax Obligations - TradingView
First Week of April 17th Options Trading For Dyne Therapeutics (DYN) - Nasdaq
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Myotonic Dystrophy Pipeline Analysis 2024: FDA Approvals - openPR
Bronstein, Gewirtz & Grossman, LLC Is Investigating Dyne Therapeutics, Inc.(DYN) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics, Inc.(DYN) Investors to Inquire about Securities Investigation - ACCESS Newswire
Dyne therapeutics SVP Richard Scalzo sells $34,707 in stock By Investing.com - Investing.com Nigeria
Dyne therapeutics SVP Richard Scalzo sells $34,707 in stock - Investing.com India
Dyne Therapeutics Officer Sells Shares to Satisfy Tax Obligations - TradingView
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
(DYN) Technical Data - Stock Traders Daily
Dyne Therapeutics (NASDAQ:DYN) Sets New 52-Week LowWhat's Next? - MarketBeat
abrdn plc Makes New Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Dyne Therapeutics to Present Key Data from DELIVER and ACHIEVE Clinical Trials at 2025 MDA Conference - Nasdaq
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific - The Bakersfield Californian
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference - GlobeNewswire
Major Clinical Data Alert: Dyne's DMD and DM1 Trial Results Set for Exclusive MDA Conference Reveal - StockTitan
After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN) - Yahoo Finance
Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 5%Here's What Happened - MarketBeat
abrdn plc Purchases New Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics To Present At Oppenheimer Healthcare Conference; Webcast At 4:00 PM ET - Nasdaq
Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics, Inc. (DYN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Dyne Therapeutics (NASDAQ:DYN) Trading Up 7%Time to Buy? - MarketBeat
Dyne Therapeutics Shares Rise Premarket as DMD Study Gets FDA Nod -July 05, 2022 at 08:18 am EDT - Marketscreener.com
Jennison Associates LLC Sells 135,037 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Dyne Therapeutics, Inc. (DYN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
3.23%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):